Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLG AMLM28 ADAPT platform trial in newly diagnosed AML unfit for intensive chemotherapy
ACTRN12623000900617Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax and azacitidine in acute myeloid leukemia (AML) (5 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Development of centralized MRD monitoring network. Started May 2026; status: recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12623000900617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000900617.